

## DAFTAR PUSTAKA

- A. Jigisha, R. Nishant, K. Navin et al. (2012). "Green tea: a magical herb with miraculous outcomes," *International Research Journal of Pharmacy*, vol. 3, no. 5, pp. 139–148.
- Abbas A, Litchman A, Pillai S. (2019). *Basic Immunology- Functions and Disorders of the Immune System 6th Edition*. 6th Editio. Elsevier Inc.
- Adami AG, Gallo JF, Pinhata JMW, Martins MC, Giampaglia CMS, de Oliveira RS. (2017). Modified protocol for drug susceptibility testing of MGIT cultures of *Mycobacterium tuberculosis* by the MGIT 960. *Diagn Microbiol Infect Dis*.
- Al, X. Z. E. T., Zheng, X., Forsman, L. D., Bao, Z., Xie, Y., Ning, Z., & Schön, T. (2022). Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China. July 2021. <https://doi.org/10.1183/13993003.01925-2021>
- Allué-Guardia, A., Saranathan, R., Chan, J., and Torrelles, J.B. (2021). Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis. *Int. J. Mol. Sci.* (pp. 22, 735). <https://doi.org/10.3390/ijms22020735>.
- Anand PK, Kaul D, Sharma M. (2006). Green tea polyphenol inhibits *Mycobacterium tuberculosis* survival within human macrophages. *The International Journal of Biochemistry and Cell Biology*.
- Ang F, RMT, Myrna T. Mendoza, MD, Heidi R. Santos, Regina Celada-Ong, Carmela P. Enrile, Wilma C. Bulatao and Aileen M. Aguila. (2011). Isolation Rates of *Mycobacterium tuberculosis* from Smearnegative and Smear-positive Sputum Specimen Using the Ogawa Culture Technique and the Standard Lowenstein Jensen Culture Technique. <http://www.psmid.org.ph/vol30/vol30num2topic1.pdf>.
- Ariami, P., Wiwin Diarti dan Yunan Jiwintarum, M., Analisis Kesehatan Poltekkes Kemenkes Mataram, J., Prabu Rangkasari Dasan Cermen Sandubaya Mataram, J., Wiwin Diarti, M., & Jiwintarum, Y. (2014). Sensitivitas Media Ogawa Dan Media Lowenstein Jensen Terhadap Hasil Pertumbuhan Kuman *Mycobacterium Tuberculosis*. *Jurnal Kesehatan Prima*, 8(2), 1322–1335. <http://www.scribd.com>
- Balai Besar Laboratorium Kesehatan. (2022). LRN Biakan dan Uji Kepekaan Tuberkulosis. Surabaya
- Bansal et al. (2013). Tea: A native source of antimicrobial agents. *Food Research International*. (pp. 568–584). <http://dx.doi.org/10.1016/j.foodres.2013.01.032>.
- Barber-Mayer KD, Barber DL. (2015). Innate and adaptive cellular immune responses to *Mycobacterium tuberculosis* infection. *Cold Spring Harb Perspect Med*.

- Bashir, A.S.B. Basharat A. Ahmad, Z. Mir, M.A. (2022). Strategies Employed to Evade the Host Immune Response and the Mechanism of Drug Resistance in *Mycobacterium tuberculosis*: In Search of Finding New Targets. *Current Pharmaceutical Biotechnology*, Volume 23, Number 14, pp. 1704-1720(17).
- Batt, S. M., Burke, C. E., Moorey, A. R., & Besra, G. S. (2020). Antibiotics and resistant : the two-sided coin of the mycobacterial cell wall. *The Cell Surface*, 6(August), 100044.
- Biokamga, V.I., Yande, H.K., Kouipou, R.M.T., Kanko, M.I.M., Arc-En-Ce, J.M., Kammalac, T.N., and Boyom, F.F. (2016). Effect of Combined Extract from Different Plant Parts of *Annona senegalensis* on Antibacterial and Antifungal Activities. *International Journal of Pharmacognosy and Phytochemical Research*.
- Boutte, C. C. (n.d.). (2019). The mycobacterial cell envelope — a moving target. *Nature Reviews Microbiology*. <https://doi.org/10.1038/s41579-0190273-7>
- Brandis, G., & Hughes, D. (2018). Mechanisms of fitness cost reduction for rifampicin-resistant strains with deletion or duplication mutations in *rpoB*. *Scientific Reports*, November, 1–6. <https://doi.org/10.1038/s41598-018-36005-y>.
- Brooks, GF., Carroll KC, Butel JS, Morse. (2013). *Mikrobiologi Kedokteran Jawetz, Melnick, & Adelberg*. Ed. 25. Penerbit Buku Kedokteran EGC: Jakarta.
- Bussi, C and Gutierrez, B. G. (2019). Mycobacterium tuberculosis infection of host cells in space and time. *FEMS Microbiology Reviews*. doi: 10.1093/femsre/fuz006.
- Cummings RD. (2022). The mannose receptor ligands and the macrophage glycome. *Curr Opin Struct Biol* from: <https://www.sciencedirect.com/science/article/pii/S0959440X22000732>.
- Corleis B, Dorhoi A. Early dynamics of innate immunity during pulmonary tuberculosis. (2020). *Immunol Lett* from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082090709&doi=10.1016%2Fj.imlet.2020.02.010&partnerID=40&md5=8f3923fa809480bf5127aba1dd6e1624>
- Daulay, M., Sudarwanto, M., Nugroho, W., & Sudarnika, E. (2015). "Pengembangan Media Padat untuk Menumbuhkan *Mycobacterium bovis* (DEVELOPMENT OF SOLID MEDIUM FOR MYCOBACTERIUM BOVIS CULTIVATION)." *Jurnal Veteriner*, 16(4), 497–504. <https://doi.org/10.19087/jveteriner.2015.16.4.497>
- Difco and BBL. (2009). *Manual of Microbiological Culture Media* Second Edition. Becton, Dickinson and Company Sparks, Maryland 21152 USA.
- Diriba et al. (2017). Performance of Mycobacterium Growth Indicator Tube BACTEC 960 with Lowenstein– Jensen method for diagnosis of Mycobacterium tuberculosis at Ethiopian National Tuberculosis

- Reference Laboratory, Addis Ababa, Ethiopia. *BMC Research Notes*. DOI 10.1186/s13104-017-2497-9.
- Dubey, S. (2017). QSAR and Molecular Interaction Study of Piperine Analogues for Antitubercular Activity. *Organic & Medicinal Chemistry International Journal*, 3(2), 1–14. <https://doi.org/10.19080/omcij.2017.03.555606>.
- Eddabra, R. (2020). Mutations Associated with Rifampicin Resistance in *Mycobacterium tuberculosis* Isolates from Moroccan Patients : 2020
- Fatimah Z, Hameed S, Islam N. (2012). Epigallocatechin-3-gallate (EGCG), A Green Tea Polyphenol Suppresses Bacilli-Induced augmented Expression of *Mycobacterium tuberculosis* 85B and Proinflammatory TNF- $\alpha$  in Human Monocytes. *International Journal of Scientific and Research Publications*.
- Fatimah Z, Hameed S, Islam N. (2013). Green Tea Polyphenol (EGCG) is a Better Inhibitor of TNF- $\alpha$  and MTB 85B Antigen in Human Monocytes Than Known Antioxidants and Antibiotics. *The Journal of Infectious Disease*.
- Fa-Wei Xu, Ying-Li Lv, Yu-Fan Zhong, Ya-Nan Xue, Yong Wang, Li-Yun Zhang, Xian Hu, and Wei-Qiang Tan. (2021). Beneficial Effects of Green Tea EGCG on Skin Wound Healing: A Comprehensive Review. *Molecules* 26:20. pages 6123.
- Fennelly K. P., Jones-Lopez E. C. (2015). Quantity and quality of inhaled dose predicts immunopathology in tuberculosis. *Front Immunol.* (Vol. 6, pp. 313).
- Ferluga, J., Yasmin, H., Al-Ahdal, M. N., Bhakta, S., & Kishore, U. (2020). Natural and trained innate immunity against *Mycobacterium tuberculosis*. *Immunobiology*, 225(3), 151951. <https://doi.org/10.1016/j.imbio.2020.151951>
- Gandjar and Rohman. (2018). *Molecular Spectroscopy for Pharmaceutical Analysis. Gadjah Mada University Press.*
- Geffken, A.C., Patin, E.C., Schaible, U.E. (2015). Isolation of Bead Phagosomes to Study Virulence Function of *M. tuberculosis* Cell Wall Lipids. In: Parish, T., Roberts, D. (eds) *Mycobacteria Protocols. Methods in Molecular Biology*, vol 1285. Humana Press, New York, NY. [https://doi.org/10.1007/978-1-4939-2450-9\\_22](https://doi.org/10.1007/978-1-4939-2450-9_22).
- Garra AO, Redford PS, Mcnab FW, Bloom CI, Wilkinson RJ, Berry MPR. (2013). The Immune Response in Tuberculosis.
- Goldman E., Green L.H. (2009). *Practical Handbook of Microbiology*. CRC Press: Boca Raton.
- Goossens, SN., Sampson, SL., & Van Rie A. (2021). Mechanisms of drug-induced tolerance in *Mycobacterium tuberculosis*. *Clinical Microbiology Reviews*. <https://doi.org/10.1128/CMR.00141-20>.
- Gordon and Parish. (2018). Microbe Profile: *Mycobacterium tuberculosis*: Humanity's deadly microbial foe. *Microbiology Society*. (Vol. 164, pp. 437–439).

- Gray KJ, Gibbs JE. (2022). Adaptive immunity, chronic inflammation and the clock. *Semin Immunopathol* from: <https://doi.org/10.1007/s00281-022-00919-7>.
- H. H. Chow and I. A. Hakim.(2011). Pharmacokinetic and chemoprevention studies on tea in humans. *Pharmacol Res*; 64, 105-112.
- Harris J, Keane J. (2010). How tumour necrosis factor blockers interfere with tuberculosis immunity. *Clin Exp Immunol*.
- Hartini, S., S, O. D., & Suliati. (2018). Pertumbuhan Mycobacterium tuberculosis Pada Nutrien Agar Sebagai Mediun Alternatif. *Hospital Science*, 2(1), 1–5.
- Hasan M, Munshi SK, Banu Momi MS, Rahman F, Noor R. (2013). Evaluation of the effectiveness of BACTEC MGIT 960 for the detection of mycobacteria in Bangladesh. *Int J Mycobacteriology*.
- Hegde, P., Boshoff, H. I. M., Rusman, Y., Aragaw, W. W., Salomon, C. E., Dick, T., & Aldrich, C. C. (2021). Reinvestigation of the structure-activity relationships of isoniazid. *Tuberculosis*, 129, Article 102100. <https://doi.org/10.1016/j.tube.2021.102100>.
- Iacobino, A., Fattorini, L., & Giannoni, F. (2020). Drug-resistant tuberculosis. Where we stand. *Applied Sciences (Switzerland)*, 10(6), 1–17. <https://doi.org/10.3390/app10062153>
- Jiang T, Li L, Du Y, Zang S, Xie Y, Liu Z, Xin Y. 2012. Inhibitory effect of crude extract from green tea on Mycobacterium smegmatis mc2 155. *Nat Prod Res Dev*. 24:84–88.
- K. Tanigawa et al. (2009). Tryptophan aspartate-containing coat protein (CORO1A) suppresses Toll-like receptor signalling in Mycobacterium leprae infection. *British Society for Immunology, Clinical and Experimental Immunology*.
- Kandler JL, Mercante AD, Dalton TL, Ezewudo MN, Cowan LS, Burns SP, Metchock B, on behalf of Global PETTS Investigators, Cegielski P, Posey JE. (2018). Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests. *Antimicrobial Agents and Chemotherapy*. <https://doi.org/10.1128/AAC.00974-18>.
- Kapp, E., Malan, S. F., Joubert, J., & Sampson, S. L. (2017). Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: A Rational Drug Design Perspective. *Mini-Reviews in Medicinal*
- Kaur, R., & Kaur, H. (2015). Antitubercular Activity and Phytochemical Screening of Selected Medicinal Plants.
- Kementerian Kesehatan RI. (2018). Petunjuk Teknis Pemeriksaan Paket Standar Uji Kepekaan Mycobacterium tuberculosis. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit.
- Kocch KR, Wachira FN, Ngure RM, Wanyoko JK, Bii CC, Karori SM, et al. (2013). Antimicrobial, Synergistic and Antioxidant Activities of Tea Polyphenols. In: A Mendez-Vilas, Ed. *Microbial Pathogens and*

- Strategies for Combating Them: Science, Technology and Education. Badajoz: Formatex Research Center.
- Krinke G.J. (2000). The Handbook of Experimental Animals: The Laboratory Rat. London. Academic Press.
- Kul D. (2020). Electrochemical Determination of Rifampicin Based on Its Oxidation Using Multi-Walled Carbon Nanotube-Modified Glassy Carbon Electrodes. *Turk J Pharm Sci.* 17(4):398-407. doi: 10.4274/tjps.galenos.2019.33600.
- Li Ma chao., Jie Lu., Yao Lu., Tong-yang Xiao., Hai-can Liu., Shi-qiang Lin., Da Xu., Gui-lian Li., Xiu-qin Zhao., Zhi-guang Liu., Li-li Zhao and Kang-lin Wan. (2021). *rpoB* Mutations and Effects on Rifampin Resistance in *Mycobacterium tuberculosis*. *Infect Drug Resist.* 14: 4119–4128. doi: 10.2147/IDR.S333433.
- Luies, L., & Preez, I. du. (2020). The echo of pulmonary tuberculosis: Mechanisms of clinical symptoms and other disease-induced systemic complications. *Clinical Microbiology Reviews*, 33(4), 1–19. <https://doi.org/10.1128/CMR.00036-20>.
- Maitra, A. Tulika Munshi. Jess Healy. Liam T. Martin. Waldemar Vollmer. Nicholas H. Keep and Sanjib Bhakta. (2019). Cell wall peptidoglycan in *Mycobacterium tuberculosis*: An Achilles' heel for the TB-causing pathogen. *FEMS Microbiology Reviews*, 2019, Vol. 43, No. 5
- Matty MA, Roca FJ, Cronan MR, Tobin DM, Tobin DM. (2015). Adventures within the speckled band : heterogeneity , angiogenesis , and balanced inflammation in the tuberculous granuloma.
- Mertaniasih NM, Khaendori EB, Kusumaningrum D. (2013). *Buku Ajar Tuberkulosis Diagnostik Mikrobiologi*. Surabaya: Pusat Penerbitan dan Percetakan Universitas Airlangga.
- Mirzautika, A., Isnaeni & Djoko A. P. (2020). Anti-*Mycobacterium tuberculosis* Activity of (-)-Epigallocatechin-gallate (EGCG) and First Line Antituberculosis Drugs Combination. *Jurnal Kefarmasian Indonesia*. 10(1):59-66.
- Musial, C., Jankowska A. K., and Ponikowska, M. G. (2020). Beneficial Properties of Green Tea Catechins. *Int. J. Mol. Sci.* doi:10.3390/ijms21051744.
- Nambiar R, Chatellier S, Bereksi N, van Belkum A, Singh N, Barua B, et al. (2017). Evaluation of Mycotube, a modified version of Lowenstein-Jensen (LJ) medium, for efficient recovery of mycobacterium tuberculosis (MTB). *Eur J Clin Microbiol Infect Dis*.
- Natarajan K, Kundu M, Sharma P, Basu J. (2011). Innate immune responses to *M. tuberculosis* infection. *Tuberculosis from:* <http://dx.doi.org/10.1016/j.tube.2011.04.003>
- Pakadang SR, Hilaria M, Dewi STR, Sinala S, Jumain. (2021). MIC and MKC Analysis of Herbal Medicine in Indonesia Against *Mycobacterium tuberculosis*. *Pharmacogn J.*13(5): 1058-1064.
- Parvez MAK, Saha K, Rahman J, Munmun RA, Rahman MA, Dey SK, Rahman MS, Islam S, Shariare MH. (2019). Antibacterial activities of

- green tea crude extracts and synergistic effects of epigallocatechingallate (EGCG) with gentamicin against MDR pathogens. *Heliyon*. Doi: 10.1016/j.heliyon.2019.e02126. PMID: 31372566; PMCID: PMC6658803.
- P. Chaterjee, S. Chandra, P. Dey et al. (2012). "Evaluation of antiinflammatory effects of green tea and black tea: a comparative in vitro study," *Journal of Advanced Pharmaceutical Technology & Research*, vol. 3, no. 2, pp. 136–138.
- Polena H, Boudou F, Tilleul S, Dubois-Colas N, Lecointe C, Rakotosamimanana N. (2016). *Mycobacterium tuberculosis* exploits the formation of new blood vessels for its dissemination. *Sci*.
- Pooja, H., Helena I. M. B., Yudi, R., Wassihun, W. A., Christine, E. S., Thomas, D., & Courtney, C. A. (2021). Reinvestigation of the structure-activity relationships of isoniazid. *at Science Direct Tuberculosis journal*. <https://doi.org/10.1016/j.tube.2021.102100>.
- Purwanti, R. D., Hanafiah, A., & Oekar, N. K. (2013). Uji Resistensi *Mycobacterium Tuberculosis* Terhadap Kombinasi Isoniazid dan Etambutol dengan Teknik Nuklir. *Indonesian Journal of Pharmaceutical Science and Technology*, 11(2), 34–48.
- Puspasari, S. F. (2019). *Asuhan Keperawatan Pada Pasien Dengan Gangguan Sistem Pernapasan*. Yogyakarta: Pustaka Baru.
- Qin S, Chen R, Jiang Y, Zhu H, Chen L, Chen Y. (2021). International Immunopharmacology Multifunctional T cell response in active pulmonary tuberculosis patients. *Int Immunopharmacol* from: <https://doi.org/10.1016/j.intimp.2021.107898>.
- Rageade F, Picot N, Blanc-Michaud A, Chatellier S, Mirande C, Fortin E, et al. (2014). Performance of solid and liquid culture media for the detection of *Mycobacterium tuberculosis* in clinical materials: Meta-analysis of recent studies. Vol. 33, *European Journal of Clinical*.
- Rajaram MVS, Arnett E, Azad AK, Guirado E, Ni B, Gerberick AD. (2017). *M. tuberculosis*-Initiated Human Mannose Receptor Signaling Regulates Macrophage Recognition and Vesicle Trafficking by FcRγ-Chain, Grb2, and SHP-1. *Cell Rep*.
- Ravimohan, S., Kornfeld, H., Weissman, D., & Bisson, G. P. (2018). Tuberculosis and lung damage: From epidemiology to pathophysiology. *European Respiratory Review*, 27(147). <https://doi.org/10.1183/16000617.0077-2017>
- Reygaert WC. (2014). The antimicrobial possibilities of green tea. *Front Microbiol*. doi: 10.3389/fmicb.2014.00434. PMID: 25191312; PMCID: PMC4138486.
- Reygaert, W. C. (2018). Green Tea Catechins: Their Use in Treating and Preventing Infection Diseases. *Biomed Research International*. (pp.1-9).
- Rosyidah F, Mertaniasih NM, Isnaeni. (2020). Evaluation of IFN-γ level in peripheral blood mononuclear cell of childhood tuberculosis treated


- by lactic acid bacteria multi cultures. Vol. 24, Journal of Research in Pharmacy. p. 188–95.
- Sakamoto, K. (2012). The Pathology of Mycobacterium tuberculosis Infection. *Veterinary Pathology*, 49(3), 423–439. <https://doi.org/10.1177/0300985811429313>
- Setiyowati, E. Hardiyanti. Priyo Susilo. Ferry, AS. (2021). Overview Self-Efficacy and Self-Acceptance in Tuberculosis Sufferers. University of Nahdlatul Ulama Surabaya.
- Sharma, SK. Mohan, A. (2004). Multidrug-resistant Tuberculosis. Review Article. *Indian Journal Med Res*.
- Sharma, SK. Mohan, A. (2006). Multidrug-resistant Tuberculosis. A Menace That Threatens to Destabilize Tuberculosis Control. *Global Medicine*.
- Sharma, SK P. Parasuraman, G. Kumar, N. Surolia, A. Surolia. (2008). Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from *Plasmodium falciparum* (PfENR). *J. Med. Chem.* 50 (4) 765–775.
- Sharp P., Villano J. (2013). *The Laboratory Rat* Second Edition. CRC Press USA.
- Shinde, S.; Lee, L.H.; Chu, T. (2021). Inhibition of Biofilm Formation by the Synergistic Action of EGCG-S and Antibiotics. *Antibiotics*. 10: 102. <https://doi.org/10.3390/antibiotics10020102>.
- Shao SL, Cong HY, Wang MY, Liu P. (2020). The diagnostic roles of neutrophil in bloodstream infections. *Immunobiology from*: <https://doi.org/10.1016/j.imbio.2019.10.007>
- Silva PEAD, Palomino JC. (2011). Molecular Basis and Mechanism of Drug Resistance in *Mycobacterium tuberculosis*: Classical and New Drugs. *Journal of Antimicrobial Chemotherapy*.
- Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020). Recent updates on drug resistance in *Mycobacterium tuberculosis*. *Journal of Applied Microbiology*, 128(6), 1547–1567. <https://doi.org/10.1111/jam.14478>
- Siriphap, A., Kiddee, A., Duangjai, A., Yosboonruang, A., Pook-In, G., Saokaew, S., Sutteinkul, O., Rawangkan, A. (2022). Antimicrobial Activity of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) against Clinical Isolates of Multidrug-Resistant *Vibrio cholera* *Antibiotics*. <https://doi.org/10.3390/antibiotics11040518>
- Steinmann J, Buer J, Pietschmann T, Steinmann E. (2013). Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. *Br J Pharmacol*. Mar;168(5):1059-73. doi: 10.1111/bph.12009. PMID: 23072320; PMCID: PMC3594666.
- Stinson, KW et al. (2014). *Mycobacteriology Laboratory Manual* First Edition. Global Laboratory Initiative.
- Sulistia GG. (2007). *Farmakologi dan Terapi*, Edisi 5. Balai Penerbit FKUI. Jakarta.

- Tille, P. M. (2017). Bailey & Scott's Diagnostic Microbiology. In *Basic Medical Microbiology* (fourteenth, p. 45). St. Louis Missouri: Elsevier
- T. Guo, D. Song, L. Cheng. (2019). Interactions of tea catechins with intestinal microbiota and their implication for human health. *Food Sci Biotechnol*; 28, 1617-1625.
- Unissa, A. N., Subbian, S., Elizabeth, L., & Selvakumar, N. (2016). Overview on mechanisms of isoniazid action and resistance in *Mycobacterium tuberculosis*. MEEGID. <https://doi.org/10.1016/j.meegid.2016.09.004>
- Vilchèze and Jacobs. (2019). The Isoniazid Paradigm of Killing, Resistance, and Persistence in *Mycobacterium tuberculosis*. *J Mol Biol*.
- Wahdi, A dan Dewi. (2021). Mengenal Tuberkulosis. Pena Persada. Jawa Tengah.
- Yelamanchi, S.D., Mishra, A., Behra, S.K., Karthikkeyan, G., Keshava Prasad, T.S., Surolia, A. (2022). Rifampicin-Mediated Metabolic Changes in *Mycobacterium tuberculosis*. *Metabolites* 2022, 12, 493. <https://doi.org/10.3390/metabo12060493>.
- Zhao Z, Feng M, Wan J, Zheng X, Teng C, Xie X, Pan W, Hu B, Huang J, Liu Z, Wu J, Cai S. (2021). Research progress of epigallocatechin-3-gallate (EGCG) on anti-pathogenic microbes and immune regulation activities. *Food Funct*; Oct 19;12(20):9607-9619. doi: 10.1039/d1fo01352a. PMID: 34549212.
- Zuiga, J., Torres-García, D., Santos-Mendoza, T., Rodriguez-Reyna, T. S., Granados, J., & Yunis, E. J. (2012). Cellular and humoral mechanisms involved in the control of tuberculosis. *Clinical and Developmental Immunology*, 2012(May). <https://doi.org/10.1155/2012/193923>.



## LAMPIRAN

### Lampiran 1. Skema Kerja Penelitian (Pengujian Sampel hingga Penarikan Kesimpulan)



## Lampiran 2. Perhitungan Konsentrasi Sampel Uji

- a. Perhitungan pelarut untuk membuat larutan stok Epigallokatekin Galat (EGCG) sebanyak 50,4 mg = 50.400  $\mu\text{g}$  dengan konsentrasi 25.200 ppm.

$$\begin{aligned} \text{Volume Pelarut} &= \frac{\text{Jumlah Sampel Uji } (\mu\text{g})}{\text{Konsentrasi } \frac{\mu\text{g}}{\text{mL}}} \\ &= \frac{50.400(\mu\text{g})}{25.200 \frac{\mu\text{g}}{\text{mL}}} \\ &= 2 \text{ mL} \end{aligned}$$

- b. Perhitungan untuk membuat konsentrasi : 37,5 bpj, 75 bpj, 150 bpj dan 300 bpj sampel uji Epigallokatekin Galat (EGCG).

Rumus:

$$C_1 \times V_1 = C_2 \times V_2$$

$C_1$ : Konsentrasi stok awal

$V_1$ : Volume larutan stok yang diambil

$C_2$ : Konsentrasi yang diinginkan

$V_2$ : Volume total yang dibuat

1. 37,5 bpj

$$\begin{aligned} C_1 \times V_1 &= C_2 \times V_2 \\ 3.150 \text{ bpj} \times 100 \mu\text{L} &= C_2 \times 8.400 \mu\text{L} \\ C_2 &= \frac{3.150 \text{ bpj} \times 100 \mu\text{L}}{8.400 \mu\text{L}} \\ C_2 &= 37,5 \text{ bpj} \end{aligned}$$

2. 75 bpj

$$C_1 \times V_1 = C_2 \times V_2$$

$$6.300 \text{ bpj} \times 100 \mu\text{L} = C_2 \times 8.400 \mu\text{L}$$

$$C_2 = \frac{6.300 \text{ bpj} \times 100 \mu\text{L}}{8.400 \mu\text{L}}$$

$$C_2 = 75 \text{ bpj}$$

3. 150 bpj

$$C_1 \times V_1 = C_2 \times V_2$$

$$12.600 \text{ bpj} \times 100 \mu\text{L} = C_2 \times 8.400 \mu\text{L}$$

$$C_2 = \frac{12.600 \text{ bpj} \times 100 \mu\text{L}}{8.400 \mu\text{L}}$$

$$C_2 = 150 \text{ bpj}$$

4. 300 bpj



$$C_1 \times V_1 = C_2 \times V_2$$

$$25.200 \text{ bpj} \times 100 \mu\text{L} = C_2 \times 8.400 \mu\text{L}$$



$$C_2 = \frac{25.200 \text{ bpj} \times 100 \mu\text{L}}{8.400 \mu\text{L}}$$

$$C_2 = 300 \text{ bpj}$$


### Lampiran 3. Grafik Pertumbuhan terhadap Bakteri H37Rv



### Lampiran 4. Grafik Pertumbuhan terhadap Bakteri MDR





## Lampiran 5. Dokumentasi Penelitian



Alat dan Bahan



EGCG



Pembuatan dan penyaringan larutan stok EGCG



Dimasukkan 0,1 mL kontrol uji (EGCG) kedalam tabung mgit



0,8 mL suplemen sire yang telah berisi 7 mL media mgit



Inokulasi 0,5 mL bakteri H37Rv & MDR ke dalam tabung MGIT



Dimasukkan 0,1 mL OAT lini pertama sebagai kontrol positif



Kontrol uji, kontrol positif, dan kontrol negatif (H37Rv)




Kontrol uji, kontrol positif, dan kontrol negatif (MDR)



Mesin BACTEC MGIT 960



Scan tabung pada mesin MGIT



Tabung diletakkan dalam drawer dan diinkubasi selama  $\pm$  14 hari

## Lampiran 6. Hasil TCM

Test Report

Patient ID: 7309017112640064  
Sample ID: [REDACTED]  
Test Type: Specimen  
Sample Type:

Assay Information

Assay	Assay Version	Assay Type
Xpert MTB-RIF Assay G4	6	In Vitro Diagnostic

Test Result: MTB DETECTED LOW;  
Rif Resistance DETECTED

Lampiran 7. Hasil Uji Aktivitas Antibakteri Kombinasi Epigallokatekin Galat (EGCG) dan OAT (isoniazid dan rifampisin) terhadap Bakteri H37Rv dan MDR.

Sequence No:	Access No:	Isolate No:	TIP:	SOP:	Removed Date:
439550123425	MDR	1	7:1	06/14/23	06/22/23
PENELITIAN JUNE23					
Tube Position	Growth Unit	Status	Concentration	Drug Name	
C/D01	400	0	ug/ml	Growth Control	#1
C/D02	400	0	ug/ml	Undefined Drug	#2
C/D03	400	0	ug/ml	Undefined Drug	#3
C/D04	400	0	ug/ml	Undefined Drug	#4
C/D05	400	0	ug/ml	Undefined Drug	#5
INH + RIF + EGCG					
H37Rv					
43955013332	H37Rv	1	7:15	06/14/23	06/22/23
PENELITIAN JUNE23					
Tube Position	Growth Unit	Status	Concentration	Drug Name	
C/E01	400	0	ug/ml	Growth Control	#1
C/E02	0	0	ug/ml	Undefined Drug	#2
C/E03	0	0	ug/ml	Undefined Drug	#3
C/E04	0	0	ug/ml	Undefined Drug	#4
C/E05	0	0	ug/ml	Undefined Drug	#5
INH + RIF + EGCG					
H37Rv					
43955012553	H37Rv	1	7:10	06/14/23	06/22/23
PENELITIAN JUNE23					
Tube Position	Growth Unit	Status	Concentration	Drug Name	
C/D06	400	0	ug/ml	Growth Control	#1
C/D07	0	0	ug/ml	Undefined Drug	#2
C/D08	0	0	ug/ml	Undefined Drug	#3
C/D09	0	0	ug/ml	Undefined Drug	#4
C/D10	0	0	ug/ml	Undefined Drug	#5
INH + RIF + EGCG					
MDR					
43955012509	MDR	2	8:0	06/14/23	06/22/23
PENELITIAN JUNE23					
Tube Position	Growth Unit	Status	Concentration	Drug Name	
C/D01	400	0	ug/ml	Growth Control	#1
C/D02	400	0	ug/ml	Undefined Drug	#2
C/D03	400	0	ug/ml	Undefined Drug	#3
C/D04	400	0	ug/ml	Undefined Drug	#4
C/D05	400	0	ug/ml	Undefined Drug	#5
INH + RIF + EGCG					
MDR					
439550133458	MDR	2	8:10	06/14/23	06/23/23
PENELITIAN JUNE23					
Tube Position	Growth Unit	Status	Concentration	Drug Name	
C/D06	400	0	ug/ml	Growth Control	#1
C/D07	400	0	ug/ml	Undefined Drug	#2
C/D08	400	0	ug/ml	Undefined Drug	#3
C/D09	400	0	ug/ml	Undefined Drug	#4
C/D10	400	0	ug/ml	Undefined Drug	#5
INH + RIF + EGCG					
H37Rv					
439550125569	H37Rv	1	8:3	06/14/23	06/23/23
PENELITIAN JUNE23					
Tube Position	Growth Unit	Status	Concentration	Drug Name	
C/D16	400	0	ug/ml	Growth Control	#1
C/D17	0	0	ug/ml	Undefined Drug	#2
C/D18	0	0	ug/ml	Undefined Drug	#3
C/D19	0	0	ug/ml	Undefined Drug	#4
C/D20	0	0	ug/ml	Undefined Drug	#5
INH + RIF + EGCG					